Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
SUIC Sino United Worldwide Consolidated Ltd
PSRU Valiant Eagle Inc
ON ON Semiconductor Corp
KHC Kraft Heinz Co
SUMO Sumo Logic Inc
TPGY+ TPG Pace Beneficial Finance Corp. *W EXP 10/09/2027
CSTA^ Constellation Acquisition Corp I
HFBL Home Federal Bancorp Inc of Louisiana
FSEA First Seacoast Bancorp
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Closing Price
$115.42
Day's Change
-0.82 (-0.71%)
Bid
--
Ask
--
B/A Size
--
Day's High
116.36
Day's Low
114.87
Volume
(Light)
Volume:
4,471,372

10-day average volume:
7,508,794
4,471,372

LAWSUITS FILED AGAINST BLUE, CLOV and KRMD - Jakubowitz Law Pursues Shareholders Claims

11:49 am ET April 5, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / April 5, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

bluebird bio, Inc. (NASDAQ:BLUE)

CONTACT JAKUBOWITZ ABOUT BLUE:

https://claimyourloss.com/securities/bluebird-bio-inc-loss-submission-form/?id=14366&from=1

Class Period : May 11, 2020 - November 4, 2020

Lead Plaintiff Deadline : April 13, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) data supporting bluebird's BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company's BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Clover Health Investments, Corp. (NASDAQ:CLOV)

CONTACT JAKUBOWITZ ABOUT CLOV:

https://claimyourloss.com/securities/clover-health-investments-corp-loss-submission-form/?id=14366&from=1

Class Period : October 6, 2020 - February 3, 2021

Lead Plaintiff Deadline : April 6, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Clover was the recipient of a Civil Investigative Demand from the DOJ; (ii) much of Clover's sales are driven by a major related party deal that Clover not only failed to disclose but took active steps to conceal; (iii) Clover's

subsidiary Seek Insurance failed to disclose its relationship with Clover and misled consumers as to its purported independence; (iv) Clover's software was in fact rudimentary; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Repro Med Systems, Inc. (NASDAQ:KRMD)

CONTACT JAKUBOWITZ ABOUT KRMD:

https://claimyourloss.com/securities/repro-med-systems-inc-loss-submission-form/?id=14366&from=1

Class Period : August 4, 2020 - January 25, 2021

Lead Plaintiff Deadline : May 25, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) starting in January 2020, Repro Med Systems ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company's net sales were reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Image: https://www.accesswire.com/users/newswire/images/638971/tj_logo_bluegrey.png

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW

1140 Avenue of the Americas

9th Floor

New York, New York 10036

T: (212) 867-4490

F: (212) 537-5887

SOURCE: Jakubowitz Law

View source version on accesswire.com:

https://www.accesswire.com/638971/LAWSUITS-FILED-AGAINST-BLUE-CLOV-and-KRMD--Jakubowitz-Law-Pursues-Shareholders-Claims

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.